NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

Time is an aspect of keeping an expectation one gives out to shareholders (NWBO makes few promises at this point that are enforceable).

After long enough, time becomes nearly as important as the quality of what is (eventually) delivered.

If I tell the 70+ year olds and 80+ year olds here that NWBO will hit $50 a share suddenly but not for another 5 years, then the time factor makes the quality of the outcome far less impactful. Even the 50+ year olds 60+ year olds are losing prime years to enjoy the money.

That said NWBO shareholders can, after each delay, just decide to keep lowering their expectations in terms of the eventual payout and how long it will take to get there. While they don’t get voted free shares like management they can ante up more and lower their dollar cost average a bit, though being overweight in NWBO that is not risk-free as time is a factor.

Patients, well, patients don’t have that luxury, not the ones who need L and not the ones who need Direct though by the time Durect ever hits the market most of the patients in dire need will sadly not be concerned at all.

Hopefully 2023 is the last year we ever have to have this discussion but that’s up to NWBO and what kind of relationship they’ve built with regulators. Hopefully their slowness and silence (beyond what the law requires) earned many brownie points with FDA and MHRA they will finally cash in.